- Home
- CODI vs ATXS Comparison
CODI vs ATXS Comparison
Compare CODI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODI
- ATXS
- Stock Information
- Founded
- CODI 2005
- ATXS 2008
- Country
- CODI United States
- ATXS United States
- Employees
- CODI N/A
- ATXS N/A
- Industry
- CODI Home Furnishings
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CODI Consumer Discretionary
- ATXS Health Care
- Exchange
- CODI Nasdaq
- ATXS Nasdaq
- Market Cap
- CODI 480.0M
- ATXS 401.2M
- IPO Year
- CODI 2006
- ATXS 2015
- Fundamental
- Price
- CODI $6.63
- ATXS $5.81
- Analyst Decision
- CODI Buy
- ATXS Strong Buy
- Analyst Count
- CODI 2
- ATXS 7
- Target Price
- CODI $26.00
- ATXS $32.43
- AVG Volume (30 Days)
- CODI 1.6M
- ATXS 364.9K
- Earning Date
- CODI 07-30-2025
- ATXS 08-11-2025
- Dividend Yield
- CODI 15.11%
- ATXS N/A
- EPS Growth
- CODI N/A
- ATXS N/A
- EPS
- CODI N/A
- ATXS N/A
- Revenue
- CODI $2,198,233,000.00
- ATXS N/A
- Revenue This Year
- CODI $8.09
- ATXS N/A
- Revenue Next Year
- CODI $7.62
- ATXS N/A
- P/E Ratio
- CODI N/A
- ATXS N/A
- Revenue Growth
- CODI 11.87
- ATXS N/A
- 52 Week Low
- CODI $6.00
- ATXS $3.56
- 52 Week High
- CODI $24.59
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- CODI 40.43
- ATXS 58.38
- Support Level
- CODI $6.14
- ATXS $5.26
- Resistance Level
- CODI $6.62
- ATXS $5.79
- Average True Range (ATR)
- CODI 0.28
- ATXS 0.38
- MACD
- CODI 0.26
- ATXS -0.04
- Stochastic Oscillator
- CODI 89.86
- ATXS 63.64
About CODI D/B/A Compass Diversified Holdings Shares of Beneficial Interest
Compass Diversified Holdings is a diversified business conglomerate based in the United States having two groups: branded consumer business and industrial business. Branded consumer businesses are characterized as those businesses that capitalize on a valuable brand name in their respective market sector. It includes 5.11, Ergobaby, Liberty Safe, and Velocity Outdoor. Industrial businesses are characterized as those businesses that focus on manufacturing and selling particular products and industrial services within a specific market sector. The company has operations in the United States, Canada, Europe, Asia Pacific, and other International areas.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.